Trials / Completed
CompletedNCT04351763
Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 804 (actual)
- Sponsor
- Nicolaus Copernicus University · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
There is an urgent need for effective therapies against the novel COVID-19 virus. Studies have shown that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with confirmed COVID-19 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amiodarone | Ion channel blocker |
| DRUG | Verapamil | Ion channel blocker |
Timeline
- Start date
- 2020-05-20
- Primary completion
- 2021-05-25
- Completion
- 2021-06-05
- First posted
- 2020-04-17
- Last updated
- 2021-09-05
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT04351763. Inclusion in this directory is not an endorsement.